当前位置: 首页 >> 检索结果
2. Extrafollicular Tph2-like cell dominant tissue pathotype is associated with relapse in IgG4-related disease.
作者: Kanako Shimanuki.;Mitsuhiro Akiyama.;Koichi Saito.;Waleed Alshehri.;Takeru Maruyama.;Takanori Sasaki.;Keiko Yoshimoto.;Noriyasu Seki.;Hideto Tsujimoto.;Kenji Chiba.;Yuko Kaneko.
来源: Rheumatology (Oxford). 2026年
Relapse is common in IgG4-related disease (IgG4-RD), but reliable predictors to identify high-risk patients remain limited. We sought to identify blood and tissue immune features at the initiation of remission induction therapy associated with subsequent relapse.
3. AI-assisted rheumatology triage changes with referral framing.
作者: Mahmud Omar.;Mohammad E Naffaa.;Reem Agbareia.;Fadi Hassan.;Abdulla Watad.;Helana Jeries.;Alon Gorenshtein.;Yiftach Barash.;Olga R Brook.;Girish N Nadkarni.;Eyal Klang.
来源: Rheumatology (Oxford). 2026年
Two in three US physicians now use healthcare AI, and large language models (LLMs) are entering the triage workflows that determine which patients reach rheumatology and how quickly. We aimed to test whether nine prespecified cues in referral notes, patient descriptions and demographics shift AI-assisted triage decisions when the underlying clinical information is unchanged.
4. Isolated, metabolic, and hypertensive gout: a population-based cluster analysis of 94,759 patients.
作者: Maria Antonia Pou.;Daniel Martinez-Laguna.;Carlen Reyes.;Pau Satorra.;Cristian Tebé.;Hector Corominas.;Nicola Dalbeth.;Cesar Diaz-Torne.
来源: Rheumatology (Oxford). 2026年
People with gout exhibit significant clinical heterogeneity due to diverse comorbidity profiles. This study aimed to identify distinct clinical phenotypes using cluster analysis and to evaluate differences in management, specifically urate-lowering therapy (ULT) patterns and sustained serum urate (SU) control.
6. Biologic DMARD class influences progression from psoriasis to PsA: A real-world cohort study.
作者: Nikolaos Kougkas.;Eleni Sotiriou.;Dimitrios Deligeorgakis.;Vasileios Skepastianos.;Elpida Skouvaklidou.;Konstantinos Tsafis.;Theognosia Vergou.;Nikolaos Michalakeas.;Ilias Papadimitriou.;Theodoros Dimitroulas.;George E Fragoulis.
来源: Rheumatology (Oxford). 2026年
To evaluate whether the risk of progression from psoriasis to psoriatic arthritis (PsA) is affected by the class of bDMARD used for treatment of psoriasis, in a real-world cohort with a large follow-up.
7. Attainment of early targets does not ensure a complete response at 12 months in lupus nephritis, especially in nephrotic-range proteinuria.
作者: Maria Pappa.;Konstantinos Drougkas.;Antigone Pieta.;Maria Kosmetatou.;Spyridon Katechis.;Myrto Nikoloudaki.;Nektarios-Marios Liapis.;Christina Tsalapaki.;Evangelia Argyriou.;Theodoros Dimitroulas.;Myrto Cheila.;Charalampos Papagoras.;Andreas V Goules.;Christina Katsiari.;Dimitrios Vassilopoulos.;Paraskevi V Voulgari.;Dimitrios Boumpas.;Maria G Tektonidou.;George K Bertsias.;Antonis Fanouriakis.
来源: Rheumatology (Oxford). 2026年
EULAR recommends early proteinuria reduction targets in lupus nephritis (LN) (≥25% at 3 months and ≥50% at 6 months). We examined the predictive value of these targets for achieving complete renal response (CRR) at 12 months, a surrogate for favorable long-term outcomes.
8. Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve.
作者: Ann-Christin Pecher.;Jörg Henes.;Melanie Henes.;Claudia Lengerke.;Wolfgang Bethge.;Andreas Wirsching.;Tobias Rothe.;Fabian Müller.;Andreas Mackensen.;Georg Schett.;Melanie Hagen.
来源: Rheumatology (Oxford). 2026年
Women with systemic lupus erythematosus (SLE) are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies. Anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy has recently been shown to induce durable, drug‑free remission in refractory SLE; however, its effects on ovarian function remain unknown. We assessed longitudinal changes in reproductive endocrine markers to evaluate the impact of CAR T‑cell therapy on ovarian reserve and hypothalamic-pituitary-ovarian (HPO) axis function.
9. Detecting Sjögren's Disease from Parotid Gland Ultrasound Radiomics.
作者: Gamze Akkuzu.;Omer Faruk Durugol.;Sena Tolu.;Muhammed Furkan Dasdelen.;Mehmet Karagulle.;Kanullah Suleyman.;Bilgin Karaalioğlu.;Rabia Deniz.;Duygu Sevinç Özgür.;Fatih Yıldırım.;Cemal Bes.
来源: Rheumatology (Oxford). 2026年
Salivary gland ultrasonography is a promising non-invasive modality for the evaluation of Sjögren's disease (SjD), but its diagnostic utility is limited by operator dependency. This study aimed to evaluate the classification performance of radiomics-based machine learning using parotid gland ultrasonography and to compare it with conventional visual assessment.
10. Sleep measurement and clinical impact in osteoarthritis and inflammatory arthritis: a scoping review.
作者: Annalisa De Lucia.;Yeliz Prior.;Gianluca Bertoni.;Benedetto Giardulli.;Filippo Recenti.;Valeria Donisi.;Cinzia Perlini.;Richard Jones.;Andrea Dell'Isola.;Simone Battista.
来源: Rheumatology (Oxford). 2026年
To map how sleep has been assessed in osteoarthritis (OA) and/or inflammatory arthritis (IA), and to synthesise the evidence on the prevalence, characteristics, and relationships between sleep disturbances and these conditions.
12. Long-term effectiveness of the Early Arthritis Recognition Clinic's screening for the presence of clinical arthritis in the Netherlands: a single-centre, longitudinal cohort study.
作者: Simonetta R G van Griethuysen.;Elise van Mulligen.;Annette H M van der Helm-van Mil.
来源: Lancet Rheumatol. 2026年
General practitioner (GP) delay is the main cause of referral delay for rheumatoid arthritis in the Netherlands due to insufficient experience with joint examination. This delay led to the launch of the early arthritis recognition clinic, in which rheumatologists screen patients for clinical arthritis using joint examination. Because the long-term effectiveness of this intervention is unknown, we measured functional disability and sustained disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis to establish its effectiveness.
13. Early haematologic response to anifrolumab in systemic lupus erythematosus: results from the european multicentre EFFORT-SLE study.
作者: Michela Gasparotto.;Alessandra Bettiol.;Ginevra De Marchi.;Edoardo Biancalana.;Giulia Duro.;Filippo Fagni.;Alice Horisberger.;Joško Mitrović.;Alessia Nano.;Katarzyna Wawrzycka-Adamczyk.;Myriam Reisch.;Lea Salamon.;Georg Schett.;Ladislav Šenolt.;Elena Silvestri.;Jens Thiel.;Paola Tomietto.;Krzysztof Wójcik.;Jakub Závada.;Luca Quartuccio.;Giacomo Emmi.
来源: Rheumatology (Oxford). 2026年
To evaluate the efficacy and safety of anifrolumab (ANI) for the hematologic manifestations of systemic lupus erythematosus (SLE) in routine clinical practice.
14. Treatment strategies for relapsing IgG4-RD: twelve-year experience from a prospective cohort.
作者: Yuxue Nie.;Jialei Zhang.;Jialing Jiang.;Hui Lu.;Xinli Yang.;Jingna Li.;Nianyi Zhang.;Jie Meng.;Lidan Zhao.;Li Zhang.;Jiaxin Zhou.;Yunyun Fei.;Yan Zhao.;Xiaofeng Zeng.;Mengtao Li.;Linyi Peng.;Wen Zhang.
来源: Rheumatology (Oxford). 2026年
Relapse is common in IgG4-related disease (IgG4-RD). While previous studies focus on treatments for active IgG4-RD, data on the management of relapsing IgG4-RD remains limited. We aimed to investigate the treatment strategies for relapsing IgG4-RD.
16. Antiphospholipid antibody trajectories and clinical correlates in an inception cohort of systemic lupus erythematosus.
作者: Ritesh Kumar Mishra.;Chengappa Kavadichanda.;Priyanka Baskaran.;Subin Philip.;Rizwana Naushad.;Sriyanka Mohapatra.;Mani Rajendran.;Kalaichelvi Kalidass.;Aishwarya Gopal.;Christina Mary Mariaselvam.;Molly Mary Thabah.;Vir Singh Negi.;Amita Aggarwal.
来源: Rheumatology (Oxford). 2026年
To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage.
17. Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration.
作者: Samaneh Ghassemi.;Jasvinder A Singh.;Rong Jiang.;Yinong Young-Xu.;Francesca E Cunningham.;Peter A Glassman.;Xinhua Zhao.;Cedric Salone.;Anthony Au.;Donald R Miller.;Qoua Her.;Diane Dong.;Sherrie L Aspinall.
来源: Rheumatology (Oxford). 2026年
Real-world comparisons of rituximab biosimilars with originator rituximab have largely focused on oncology, with limited evidence in rheumatoid arthritis (RA). This gap is particularly pertinent to the Veterans Health Administration (VHA), where patients with RA are older and have greater comorbidity. We evaluated the effectiveness and safety of rituximab-pvvr versus originator rituximab in Veterans with RA by (1) describing treatment patterns, (2) assessing effectiveness, (3) evaluating adverse events, and (4) identifying reasons for switching back to the originator after initiating the biosimilar.
19. Higher mortality without increased ESKD risk in late-onset SLE with lupus nephritis versus early-onset SLE: a Latin American cohort.
作者: Natalia A Uribe-Ruíz.;Andrés Felipe Vargas-Camacho.;Lina Aguirre-Hernández.;Alejandra Taborda.;Lina Serrato-Adrada.;Mauricio Restrepo-Escobar.;Luis Alonso González.;Joaquín Rodelo-Ceballos.
来源: Rheumatology (Oxford). 2026年
To compare kidney survival, mortality, and composite outcomes in lupus nephritis (LN) according to age at systemic lupus erythematosus (SLE) onset (late-onset ≥50 years vs early-onset 18-49 years) in a Latin American cohort.
20. Medication use during pregnancy and pregnancy outcomes in women with immune mediated inflammatory diseases: a UK-based matched cohort study.
Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.
|